Cerys living with hereditary tyrosinemia type 1 (HT-1)
Swedish Orphan Biovitrum develops, manufactures and sells medications for a number of diseases, with a special emphasis on four specialist areas: haemophilia, inflammation/autoimmune diseases, inherited metabolic diseases and oncology.
We focus on medications for rare disease patients with a high unmet medical need. This category includes specialist and so-called orphan drugs, which are mainly prescribed by clinical specialists and aimed at small well-defined patient groups. These less common diseases are often neglected and inadequately treated which means that new medications can offer significant value for the patient and health care providers.
Swedish Orphan Biovitrum provides specialty pharmaceuticals throughout Europe, Canada and the US. Our presence also includes distribution partnerships giving us reach in Asia, Australia, New Zealand and South America as well.